CN110198945B - 用于制备噻唑烷二酮化合物及其盐的方法 - Google Patents

用于制备噻唑烷二酮化合物及其盐的方法 Download PDF

Info

Publication number
CN110198945B
CN110198945B CN201780084302.3A CN201780084302A CN110198945B CN 110198945 B CN110198945 B CN 110198945B CN 201780084302 A CN201780084302 A CN 201780084302A CN 110198945 B CN110198945 B CN 110198945B
Authority
CN
China
Prior art keywords
compound
solvent
reaction mixture
formula
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780084302.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110198945A (zh
Inventor
A·M·加西亚科拉佐
W·滕霍夫
J·N·科克
J·B·M·里温克尔
S·德维尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of CN110198945A publication Critical patent/CN110198945A/zh
Application granted granted Critical
Publication of CN110198945B publication Critical patent/CN110198945B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127Preparation from compounds containing pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/10Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201780084302.3A 2016-12-23 2017-12-22 用于制备噻唑烷二酮化合物及其盐的方法 Active CN110198945B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382648 2016-12-23
EP16382648.0 2016-12-23
PCT/IB2017/058374 WO2018116281A1 (en) 2016-12-23 2017-12-22 Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Publications (2)

Publication Number Publication Date
CN110198945A CN110198945A (zh) 2019-09-03
CN110198945B true CN110198945B (zh) 2023-06-27

Family

ID=57799523

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780084302.3A Active CN110198945B (zh) 2016-12-23 2017-12-22 用于制备噻唑烷二酮化合物及其盐的方法

Country Status (19)

Country Link
US (2) US11124505B2 (https=)
EP (1) EP3559010B1 (https=)
JP (2) JP7294661B2 (https=)
KR (1) KR102609373B1 (https=)
CN (1) CN110198945B (https=)
BR (1) BR112019012972B1 (https=)
CA (1) CA3046744A1 (https=)
CY (1) CY1125531T1 (https=)
DK (1) DK3559010T3 (https=)
ES (1) ES2926580T3 (https=)
HR (1) HRP20221067T1 (https=)
HU (1) HUE059604T2 (https=)
IL (1) IL267557B (https=)
LT (1) LT3559010T (https=)
MX (1) MX379709B (https=)
PL (1) PL3559010T3 (https=)
PT (1) PT3559010T (https=)
SI (1) SI3559010T1 (https=)
WO (1) WO2018116281A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926580T3 (es) 2016-12-23 2022-10-27 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma
CN112823004A (zh) 2018-06-06 2021-05-18 米尼奥尔克斯治疗有限公司 5-[[4-[2-[5-乙酰基吡啶-2-基]乙氧基]苄基]-1,3-噻唑烷-2,4-二酮及其盐的用途
EP3801515B1 (en) 2018-06-06 2025-04-09 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
CN112512524A (zh) 2018-06-06 2021-03-16 米尼奥尔克斯治疗有限公司 给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法
EP4642456A1 (en) 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149550A1 (en) * 2007-04-27 2010-02-03 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2015150476A1 (en) * 2014-04-02 2015-10-08 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231886T2 (de) * 1991-04-11 2002-03-28 Pharmacia & Upjohn Co., Kalamazoo Thiazolidindionderivate, herstellung und anwendung
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
HUP0304096A2 (hu) 2003-12-19 2005-08-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei
GB0421687D0 (en) 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
CA2594666A1 (en) 2005-02-16 2006-08-24 Micromet Ag Use of activated polymers for separation of protein and polypeptide multimers
US20090247560A1 (en) * 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
EP2855489B1 (en) * 2012-04-26 2017-01-04 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
WO2014152843A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
ES2926580T3 (es) 2016-12-23 2022-10-27 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149550A1 (en) * 2007-04-27 2010-02-03 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2015150476A1 (en) * 2014-04-02 2015-10-08 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Studies on Antidiabetic Agents.XII.1) Synthesis and Activity of the Metabolites of (±)-5-[p-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione(Pioglitazone);Takashi SOHDA et al.;《Chem.Pharm.Bull》;19951215;图1,Chart 2 *
Synthesis and Biological Activity of Metabolites of the Antidiabetic,Antihyperglycemic Agent Pioglitazone;Steven P. Tanis et al.;《J. Med. Chem.》;19961220;图2,Scheme 1 *

Also Published As

Publication number Publication date
US20190389852A1 (en) 2019-12-26
CN110198945A (zh) 2019-09-03
HRP20221067T1 (hr) 2022-11-25
IL267557B (en) 2021-10-31
EP3559010A1 (en) 2019-10-30
IL267557A (en) 2019-08-29
PL3559010T3 (pl) 2022-11-21
BR112019012972B1 (pt) 2023-04-18
SI3559010T1 (sl) 2022-10-28
PT3559010T (pt) 2022-09-01
CY1125531T1 (el) 2026-02-25
MX379709B (es) 2025-03-11
HUE059604T2 (hu) 2022-11-28
ES2926580T3 (es) 2022-10-27
KR20190100300A (ko) 2019-08-28
BR112019012972A2 (pt) 2019-12-31
US20220204496A1 (en) 2022-06-30
DK3559010T3 (da) 2022-08-15
US11731963B2 (en) 2023-08-22
JP2023052918A (ja) 2023-04-12
JP2020502228A (ja) 2020-01-23
LT3559010T (lt) 2022-10-10
EP3559010B1 (en) 2022-06-08
CA3046744A1 (en) 2018-06-28
JP7294661B2 (ja) 2023-06-20
KR102609373B1 (ko) 2023-12-01
MX2019007327A (es) 2019-09-02
WO2018116281A1 (en) 2018-06-28
US11124505B2 (en) 2021-09-21

Similar Documents

Publication Publication Date Title
CN110198945B (zh) 用于制备噻唑烷二酮化合物及其盐的方法
TW202024032A (zh) 用於製備6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯并[7]輪烯-2-甲酸甲酯之方法
JP2025183283A (ja) 選択的エストロゲン受容体分解剤の調製のためのプロセス
CN1918168B (zh) 制备3-o-保护吗啡酮和3-o-保护吗啡酮二烯醇羧酸酯的方法
US9434740B2 (en) Taxane compounds, compositions and methods
HK40013289A (en) Process for preparing thiazolidinedione compounds and salts thereof
HK40013289B (zh) 用於制备噻唑烷二酮化合物及其盐的方法
CN102656177B (zh) 螺酮缩醇衍生物的制备方法
HK40014767B (en) Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
HK40014767A (en) Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
CN116457357A (zh) 稠合的三并环衍生物及其在药学上的应用
US9309259B2 (en) Process for ixabepilone, and intermediates thereof
US20240199629A1 (en) Processes for the preparation of selective estrogen receptor degraders
WO2014108011A1 (zh) 恩替卡韦中间体及其制备方法
TW202608905A (zh) 手性胺基膦配體、包含該等配體的銥催化劑以及該等催化劑在不對稱氫化中之用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013289

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant